Nexalin Technology (NXL) Profit After Tax (QoQ) (2021 - 2026)
Nexalin Technology (NXL) Profit After Tax (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn |
| 10 | Nexalin Technology | 7.01 Mn | 6.00 Mn | 8,897.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.81% |
| Mar 31, 2026 | 11.77% |
| Dec 31, 2025 | -4.33% |
| Sep 30, 2025 | -44.07% |
| Jun 30, 2025 | 20.49% |
| Mar 31, 2025 | 29.82% |
| Dec 31, 2024 | -15.72% |
| Sep 30, 2024 | -90.66% |
| Jun 30, 2024 | -23.37% |
| Mar 31, 2024 | -33.14% |
| Dec 31, 2023 | 66.44% |
| Sep 30, 2023 | -180.52% |
| Jun 30, 2023 | -17.40% |
| Mar 31, 2023 | -2.02% |
| Dec 31, 2022 | -412.08% |
| Sep 30, 2022 | 70.72% |
| Jun 30, 2022 | -17.59% |
| Mar 31, 2022 | 34.01% |
| Dec 31, 2021 | 66.89% |